Showing results (1961-1970 of 2,046) with videos related to
Sort By:
Pageof 205
Clinical and Translational Allergy|July 23, 2020
AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI)D Ferastraoaru, H J Bax, C Bergmann, et al.Cancer Discovery|October 11, 2011
Functional viability profiles of breast cancerRachel Brough, Jessica R Frankum, David Sims, et al.Scientific Reports|November 17, 2020
VADER: a variable dose-rate external 137Cs irradiator for internal emitter and low dose rate studiesGuy Garty, Yanping Xu, Gary W Johnson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast CancerKomal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 29, 2023
Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)Alistair Ring, Lucy S Kilburn, Alex Pearson, et al.Nature Communications|September 8, 2022
Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcomaAlexandra Gyurdieva, Stefan Zajic, Ya-Fang Chang, et al.Nature|March 16, 2023
Fast and sensitive GCaMP calcium indicators for imaging neural populationsYan Zhang, Márton Rózsa, Yajie Liang, et al.Gastroenterology|February 26, 2022
Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer MicroenvironmentCarolina J Garcia Garcia, Yanqing Huang, Natividad R Fuentes, et al.ESMO Open|September 6, 2024
Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 studyH S Rugo, M Oliveira, S J Howell, et al.Science Translational Medicine|October 23, 2024
Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapyXiuting Liu, John M Baer, Meredith L Stone, et al.Pageof 205